Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 62   

Articles published

ARNA 4.60 -0.17 (-3.56%)
price chart
Is Arena The Next Alexion?
There was so much promise for the company and their recently approved drug Provenge that the valuation reached $6B for the company even before the product could hit the market. Many believers held the stock based on their ... Even though Alexion ...
Related articles »  
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) Fights for Share of Weight-loss Pill ...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA, ARNA message board) is expected to launch its patented Belviq treatment early next year, but there are some doubts that by that time Vivus, Inc. (NASDAQ:VVUS) will have made its Qsymia something of a ...
Related articles »  
With Arena, Patience Is A Virtue
Investors in Arena Pharmaceuticals (NASDAQ:ARNA) have been patient for quite some time. Early investors ... Orexigen Therapeutics (NASDAQ:OREX) is an interesting company to watch because it could very well follow in the footsteps of Arena and Vivus.
Related articles »  
Heroes And Zeros: Arena Pharmaceuticals And Avanir Pharmaceuticals
Arena Pharmaceuticals is a clinical stage biopharmaceutical company that has discovered, developed, and moved the first anti-obesity drug through FDA approval in the last 13 years in June of 2012.
Acadia Pharmaceuticals Poised For 100% Gain By December
... a company's prospects and affording investors willing to look beyond the conventional thinking an opportunity for substantial gains can be found in the positive advisory committee vote and subsequent approval of Arena Pharmaceuticals' (NASDAQ:ARNA) ...
Arena: DEA Schedule IV Will Make Belviq The Obesity Blockbuster Drug
In addition, Arena comes with some enticing benefits for a pharmaceutical suitor - 10 year Swiss Tax Haven and R&D Write-offs.
Related articles »  
Obesity Drugs Gain Attention on FDA Backing for Therapies
Third Rock Ventures is an early backer of Zafgen Inc., a biotechnology company in mid-stage trials of a therapy to treat obesity. The Food and Drug Administration cleared Belviq, from Arena Pharmaceuticals Inc. (ARNA:US) and Eisai Co. (4523), in June ...
Vivus Shares Feel The Pain: Blockbuster Diet Drug Likely Won't Be Sold ...  Forbes
Related articles »  
Promentis receives grant to develop schizophrenia drugs
Milwaukee-based Promentis Pharmaceuticals Inc. has received a three-year, $1.8 million award from the National Institutes of Health to develop more effective drugs to treat schizophrenia.
Tim Cook 'extremely sorry' about Apple Maps app
Apple CEO Tim Cook apologized Friday for the company's error-ridden new mobile mapping service, pledging to improve the application installed on tens of millions of smartphones and, in an unusual mea culpa, inviting frustrated consumers to turn to the ...
Tim Cook's Apology for Apple Maps  Investorplace.com
Related articles »  
Are Political Conventions the New Comic-Con?
Question: When you put tens of thousands of partisan supporters in one giant building for a week of showbiz and yelling, what's that called?